Cefalexin 250mg tablets Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

cefalexin 250mg tablets

alliance healthcare (distribution) ltd - cefalexin - oral tablet - 250mg

Cefalexine Kela 250 mg tabl. Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cefalexine kela 250 mg tabl.

kela sa-nv - cefalexin monohydrate 263 mg - eq. cefalexin 250 mg - tablet - 250 mg - cefalexin monohydrate 263 mg - cefalexin - dog

Cefalexin (Flynn) Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

cefalexin (flynn)

max health limited - cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml;   - granules for oral suspension - 250 mg/5ml - active: cefalexin monohydrate 52.591 mg/ml equivalent to cefalexin 50mg/ml   excipient: allura red ac dimeticone imitation guarana flavour 051880 tp0551 methylcellulose pregelatinised maize starch sodium laurilsulfate sucrose xanthan gum - cefalexin is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: - bacterial sinusitis caused by streptococci, s. pneumoniae, and staphylococcus aureus (methicillin -sensitive only); - respiratory tract infections caused by s. pneumoniae and s. pyogenes (penicillin is the usual medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever - cefalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefalexin in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present); - otitis media due to s. pneumoniae, h. influenzae, staphylococci, streptococci, and m. catarrhalis; - skin and skin-structure infections caused by staphylococci and/or streptococci; - bone infections caused by staphylococci and/or p. mirabilis; - genitourinary tract infections, including acute prostatitis, caused by e. coli, p. mirabilis, and klebsiella pneumoniae; - dental infections caused by staphylococci and/or streptococci. note - culture and susceptibility tests should be initiated prior to and during therapy. renal function studies should be performed when indicated.